{"a":[{"_":"Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint","$":{"href":"/biotech/bristol-myers-pivotal-car-t-multiple-myeloma-trial-hits-primary-endpoint","hreflang":"en"}}]}
Phase 3positiveGPRC5D-directed CAR-T cell therapyPositive
AI Analysis
Summary
Bristol Myers Squibb's pivotal trial of GPRC5D-directed CAR-T cell therapy met its primary endpoint in multiple myeloma, positioning the company to compete with Johnson & Johnson in the post-BCMA market.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Primary endpoint met in pivotal CAR-T trial for GPRC5D-directed therapy in multiple myeloma
Importance:8/10
Sentiment:
0.80
CAR-Tmultiple myelomaGPRC5Dpivotal trialprimary endpoint
Related Companies
Read the original article
Published by FierceBiotech on September 8, 2026 9:12 AM